Race to report: Are vascular endothelial growth factor genetic polymorphisms associated with outcome in advanced breast cancer patients treated with paclitaxel plus bevacizumab?

Journal of Clinical Oncology

Volumn 27, Issue 8, 2009, Pages 1342-

  Min Han, Tan ^a   Seng, Tan Chuen ^a   Yen, Lim Wei ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PACLITAXEL; VASCULOTROPIN;

ADVANCED CANCER; ALLELE; BREAST CANCER; CANCER SURVIVAL; ETHNIC DIFFERENCE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LETTER; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; VEGF GENE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; PACLITAXEL; POLYMORPHISM, SINGLE NUCLEOTIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 62449334511     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.6359     Document Type: Letter

References (2)

1. Schneider BP, Wang M, Radovich M, et al: Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26:4672-4678, 2008
2. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58:71-96, 2008